Breaking News

Today
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Periodicals
J&J reached out to vaccine rivals to study blood clot risk, WSJ reports » 09:33
04/16/21
04/16
09:33
04/16/21
09:33
JNJ

Johnson & Johnson

$160.44 /

+0.49 (+0.31%)

, PFE

Pfizer

$37.61 /

+0.45 (+1.21%)

, MRNA

Moderna

$159.85 /

-0.25 (-0.16%)

, AZN

AstraZeneca

$50.84 /

+0.97 (+1.95%)

Johnson & Johnson…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
JNJ Johnson & Johnson
$160.44 /

+0.49 (+0.31%)

PFE Pfizer
$37.61 /

+0.45 (+1.21%)

MRNA Moderna
$159.85 /

-0.25 (-0.16%)

AZN AstraZeneca
$50.84 /

+0.97 (+1.95%)

JNJ Johnson & Johnson
$160.44 /

+0.49 (+0.31%)

04/14/21 Guggenheim
Emergent BioSolutions price target lowered to $110 from $130 at Guggenheim
04/13/21 Goldman Sachs
J&J vaccine had numerical blood clot imbalance in trial, says Goldman Sachs
04/13/21 Morgan Stanley
Morgan Stanley says J&J news could improve 2022 outlook for mRNA vaccine makers
04/13/21 JPMorgan
Vaccine pause 'incremental negative' for J&J, says JPMorgan
PFE Pfizer
$37.61 /

+0.45 (+1.21%)

04/13/21 Morgan Stanley
Morgan Stanley says J&J news could improve 2022 outlook for mRNA vaccine makers
04/13/21 JPMorgan
Vaccine pause 'incremental negative' for J&J, says JPMorgan
04/09/21
Pfizer to host conference call
04/06/21 RBC Capital
Pfizer transferred with a Sector Perform at RBC Capital
MRNA Moderna
$159.85 /

-0.25 (-0.16%)

04/15/21 Piper Sandler
Moderna price target raised to $234 from $208 at Piper Sandler
04/13/21 Morgan Stanley
Morgan Stanley says J&J news could improve 2022 outlook for mRNA vaccine makers
04/13/21 Piper Sandler
Piper reiterates $208 target on Moderna after J&J Covid vaccine pause
04/07/21 Jefferies
Catalent pact with Moderna removes potential overhang, says Jefferies
AZN AstraZeneca
$50.84 /

+0.97 (+1.95%)

04/14/21 Guggenheim
Emergent BioSolutions price target lowered to $110 from $130 at Guggenheim
04/12/21
Fly Intel: Top five analyst downgrades
04/12/21 B. Riley
B. Riley calls Agenus the next Seagen, reiterates $8 target
04/12/21 Argus
AstraZeneca downgraded to Hold from Buy at Argus
JNJ Johnson & Johnson
$160.44 /

+0.49 (+0.31%)

PFE Pfizer
$37.61 /

+0.45 (+1.21%)

MRNA Moderna
$159.85 /

-0.25 (-0.16%)

AZN AstraZeneca
$50.84 /

+0.97 (+1.95%)

  • 19
    May
JNJ Johnson & Johnson
$160.44 /

+0.49 (+0.31%)

PFE Pfizer
$37.61 /

+0.45 (+1.21%)

MRNA Moderna
$159.85 /

-0.25 (-0.16%)

AZN AstraZeneca
$50.84 /

+0.97 (+1.95%)

JNJ Johnson & Johnson
$160.44 /

+0.49 (+0.31%)

PFE Pfizer
$37.61 /

+0.45 (+1.21%)

MRNA Moderna
$159.85 /

-0.25 (-0.16%)

AZN AstraZeneca
$50.84 /

+0.97 (+1.95%)

JNJ Johnson & Johnson
$160.44 /

+0.49 (+0.31%)

PFE Pfizer
$37.61 /

+0.45 (+1.21%)

MRNA Moderna
$159.85 /

-0.25 (-0.16%)

AZN AstraZeneca
$50.84 /

+0.97 (+1.95%)

Hot Stocks
Biogen presents data from portfolio of multiple sclerosis therapies » 07:33
04/16/21
04/16
07:33
04/16/21
07:33
BIIB

Biogen

$270.62 /

+4.76 (+1.79%)

Biogen announced new data…

Biogen announced new data from its portfolio of multiple sclerosis therapies to be presented at the American Academy of Neurology 2021 Virtual Annual Meeting, April 17-22. The presentations include data on quality of life benefits and analyses of extended interval dosing with TYSABRI as well as new real-world experience data from VUMERITY. The research adds to the vast clinical knowledge Biogen continues to advance as part of its commitment to the care of people living with MS. Analyses Demonstrate Improved Quality of Life Outcomes with TYSABRI and Further Evaluate Extended Interval Dosing : To better understand clinically meaningful quality of life benefits following treatment with TYSABRI, MS PATHS researchers analyzed patient reported data on 12 different domains on the Neuro-QoL questionnaire such as sleep disturbance, anxiety, fatigue, depression and participation in daily activities. Results included: In people treated with TYSABRI or Ocrevus with baseline impairment, statistically significant improvements were seen in 10 of 12 and 8 of 12 Neuro-QoL domains, respectively. In 11 of 12 domains on the Neuro-QoL questionnaire, the adjusted annualized rate of improvement was greater with TYSABRI as compared to Ocrevus. The difference between the two therapies was statistically significant in favor of TYSABRI in three of the domains: satisfaction with social roles and activities, participation in social roles and activities (p=0.0001) and emotional and behavioral dyscontrol. Neuro-QoL is an independently validated set of patient-reported outcome measurements that assess the physical, mental and social effects of people living with neurological conditions such as MS. Biogen established the MS PATHS network to foster collaboration between leading MS centers in Europe and the U.S. to help transform patient care by generating standardized data from a diverse, real-world patient population. Additionally, results from two new analyses investigating EID with natalizumab may help further inform the drug's benefit-risk profile. Biogen continues to evaluate the efficacy, safety and tolerability of natalizumab EID through the prospective NOVA trial with initial results expected in 2021. From an analysis of data in MS PATHS, natalizumab patients receiving either EID or Standard Interval Dosing had comparable real-world effectiveness on quantitative magnetic resonance imaging outcomes. An updated analysis of data from the TOUCH Prescribing Program demonstrated in the primary analysis that EID is associated with a significant 88% reduction in the risk of progressive multifocal leukoencephalopathy in comparison to the approved every four-week dose. The data, which included more patients followed for a longer period and with slightly greater exposures, reinforces results from earlier analyses of EID. Data Confirm Positive Gastrointestinal Tolerability Profile With VUMERITY in Real-World Setting: New findings on the use of VUMERITY in a real-world setting reinforce the benefits of improved gastrointestinal tolerability and confirm that the experience in clinical trials is consistent with clinical practice. In a retrospective analysis of data from December 2019 to August 2020 of 160 patients with relapsing MS, the treatment discontinuation rate due to GI side effects was low with 88.6% estimated to still be on therapy at the end of analysis and a high rate of adherence. In a subgroup of patients who switched from TECFIDERA to VUMERITY, the majority of patients switched as a result of gastrointestinal tolerability with most remaining on therapy.

ShowHide Related Items >><<
BIIB Biogen
$270.62 /

+4.76 (+1.79%)

BIIB Biogen
$270.62 /

+4.76 (+1.79%)

04/13/21 Roth Capital
Roth Capital sees Applied Genetic's XLRS licensing as vote of confidence
04/12/21 Oppenheimer
Sage Therapeutics data support 'enthusiasm' for SAGE-324 in ET, says Oppenheimer
04/12/21 Wedbush
Biogen price target raised to $245 from $236 at Wedbush
03/25/21 Piper Sandler
Piper says Biogen Tecfidera patents could change thesis, but sees unknowns
BIIB Biogen
$270.62 /

+4.76 (+1.79%)

BIIB Biogen
$270.62 /

+4.76 (+1.79%)

BIIB Biogen
$270.62 /

+4.76 (+1.79%)

BIIB Biogen
$270.62 /

+4.76 (+1.79%)

Yesterday
Periodicals
CDC advisers to tentatively reconvene next week on J&J vaccine, Bloomberg says » 18:11
04/15/21
04/15
18:11
04/15/21
18:11
JNJ

Johnson & Johnson

$160.44 /

+0.49 (+0.31%)

CDC advisers are…

CDC advisers are tentatively set to reconvene late next week to resume their talks of how to respond to a rare side effect of Johnson & Johnson's Covid vaccine, Bloomberg's Angelica LaVito reports, citing the chairman of the panel. The Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices will likely meet Thursday or Friday of next week, chairman Jose Romero said in a telephone interview. The group is weighing recommendations for J&J's shot, which has been linked to rare blood clots in the brain. Reference Link

ShowHide Related Items >><<
JNJ Johnson & Johnson
$160.44 /

+0.49 (+0.31%)

JNJ Johnson & Johnson
$160.44 /

+0.49 (+0.31%)

04/14/21 Guggenheim
Emergent BioSolutions price target lowered to $110 from $130 at Guggenheim
04/13/21 Goldman Sachs
J&J vaccine had numerical blood clot imbalance in trial, says Goldman Sachs
04/13/21 Morgan Stanley
Morgan Stanley says J&J news could improve 2022 outlook for mRNA vaccine makers
04/13/21 JPMorgan
Vaccine pause 'incremental negative' for J&J, says JPMorgan
JNJ Johnson & Johnson
$160.44 /

+0.49 (+0.31%)

JNJ Johnson & Johnson
$160.44 /

+0.49 (+0.31%)

JNJ Johnson & Johnson
$160.44 /

+0.49 (+0.31%)

JNJ Johnson & Johnson
$160.44 /

+0.49 (+0.31%)

Hot Stocks
Biogen's Tecfidera approved by China's NMPA » 16:32
04/15/21
04/15
16:32
04/15/21
16:32
BIIB

Biogen

$270.62 /

+4.76 (+1.79%)

Biogen announced that…

Biogen announced that China's National Medical Products Administration has approved TECFIDERA for the treatment of relapsing multiple sclerosis. First introduced in 2013, TECFIDERA has demonstrated a well-established safety and efficacy profile with more than 10 years of data from clinical trials and real-world experience. It has been used to treat more than 500,000 individuals with MS worldwide. The approval brings a new treatment option to people in China living with relapsing MS and also continues to expand the company's presence in the country. "It is truly a milestone to bring this well-established treatment to China and be able to help people living with relapsing multiple sclerosis," said Rachid Izzar, President, Intercontinental Region at Biogen. "We thank the NMPA for undertaking priority review to approve TECFIDERA. We are committed to expanding our presence in China and working with the MS community to address unmet medical needs through innovative therapies and solutions."

ShowHide Related Items >><<
BIIB Biogen
$270.62 /

+4.76 (+1.79%)

BIIB Biogen
$270.62 /

+4.76 (+1.79%)

04/13/21 Roth Capital
Roth Capital sees Applied Genetic's XLRS licensing as vote of confidence
04/12/21 Oppenheimer
Sage Therapeutics data support 'enthusiasm' for SAGE-324 in ET, says Oppenheimer
04/12/21 Wedbush
Biogen price target raised to $245 from $236 at Wedbush
03/25/21 Piper Sandler
Piper says Biogen Tecfidera patents could change thesis, but sees unknowns
BIIB Biogen
$270.62 /

+4.76 (+1.79%)

BIIB Biogen
$270.62 /

+4.76 (+1.79%)

BIIB Biogen
$270.62 /

+4.76 (+1.79%)

BIIB Biogen
$270.62 /

+4.76 (+1.79%)

Hot Stocks
Adverum files definitive proxy materials, accelerates ADVM-022 commercialization » 08:18
04/15/21
04/15
08:18
04/15/21
08:18
ADVM

Adverum Biotechnologies

$9.14 /

+0.13 (+1.44%)

Adverum Biotechnologies…

Adverum Biotechnologies announced that it has filed definitive proxy materials with the U.S. Securities and Exchange Commission in connection with Adverum's 2021 Annual Meeting of Stockholders, to be held virtually on May 12 at 8:30 a.m. Pacific Time. The Adverum board of directors unanimously recommends that stockholders vote the white proxy card for Adverum's three directors standing for election - Dawn Svoronos, Reed Tuckson, M.D. and Tom Woiwode, Ph.D. In conjunction with the definitive proxy filing, Adverum is mailing a letter to stockholders detailing the significant clinical advancements the board and management team are executing to accelerate toward commercialization and create value for stockholders. In the letter, the board of directors included information on accelerating ADVM-022 toward commercialization, stating, "Your Board and management team are taking decisive action to accelerate our ADVM-022 development and commercialization plans to launch our first mass-market gene therapy to treat millions of patients with wet AMD and DME if ADVM-022 receives FDA approval. We are focused on execution, with the goal of delivering this transformative gene therapy to patients globally as early as possible."

ShowHide Related Items >><<
ADVM Adverum Biotechnologies
$9.14 /

+0.13 (+1.44%)

ADVM Adverum Biotechnologies
$9.14 /

+0.13 (+1.44%)

12/15/20 UBS
Adverum Biotechnologies initiated with a Neutral at UBS
11/15/20 Piper Sandler
Adverum Biotechnologies shares should grind higher over time, says Piper Sandler
11/12/20 Raymond James
Adverum Biotechnologies upgraded to Market Perform from Underperform at Raymond James
11/12/20 Raymond James
Adverum Biotechnologies upgraded to Market Perform at Raymond James
ADVM Adverum Biotechnologies
$9.14 /

+0.13 (+1.44%)

  • 13
    Aug
Hot Stocks
Evelo Biosciences appoints Luca Scavo as CFO, Julie McHugh to board of directors » 07:09
04/15/21
04/15
07:09
04/15/21
07:09
EVLO

Evelo Biosciences

$11.15 /

-1.34 (-10.73%)

, RHHBY

Roche

$41.64 /

-0.05 (-0.12%)

, JNJ

Johnson & Johnson

$159.95 /

+0.44 (+0.28%)

Evelo Biosciences (EVLO)…

Evelo Biosciences (EVLO) announced the appointments of Luca Scavo as Chief Financial Officer, effective June 1, and Julie McHugh to its board of directors, effective immediately. Scavo brings more than 25 years of international experience and most recently served as Senior Vice President and CFO of Roche Diagnostics (RHHBY) North America. McHugh brings more than 35 years of experience in the life sciences industry, including leading the development and commercialization of products at organizations such as Johnson & Johnson (JNJ) and Nora Therapeutics.

ShowHide Related Items >><<
RHHBY Roche
$41.64 /

-0.05 (-0.12%)

JNJ Johnson & Johnson
$159.95 /

+0.44 (+0.28%)

EVLO Evelo Biosciences
$11.15 /

-1.34 (-10.73%)

EVLO Evelo Biosciences
$11.15 /

-1.34 (-10.73%)

04/12/21 Jefferies
Jefferies upgrades Evelo Biosciences to Buy on increased microbiome momentum
04/12/21 Jefferies
Evelo Biosciences upgraded to Buy from Hold at Jefferies
03/12/21 Chardan
Evelo Biosciences price target raised to $15 from $10 at Chardan
01/25/21 JMP Securities
Evelo Biosciences price target raised to $36 from $27 at JMP Securities
RHHBY Roche
$41.64 /

-0.05 (-0.12%)

04/12/21 B. Riley
B. Riley calls Agenus the next Seagen, reiterates $8 target
03/29/21 RBC Capital
PTC Therapeutics upgraded to Sector Perform at RBC Capital on valuation
03/25/21 Wedbush
iTeos Therapeutics price target raised to $52 from $46 at Wedbush
03/23/21 Truist
Truist sees mixed readthroughs to Wave's toplines from competitor HD setback
JNJ Johnson & Johnson
$159.95 /

+0.44 (+0.28%)

04/14/21 Guggenheim
Emergent BioSolutions price target lowered to $110 from $130 at Guggenheim
04/13/21 Goldman Sachs
J&J vaccine had numerical blood clot imbalance in trial, says Goldman Sachs
04/13/21 Morgan Stanley
Morgan Stanley says J&J news could improve 2022 outlook for mRNA vaccine makers
04/13/21 JPMorgan
Vaccine pause 'incremental negative' for J&J, says JPMorgan
RHHBY Roche
$41.64 /

-0.05 (-0.12%)

JNJ Johnson & Johnson
$159.95 /

+0.44 (+0.28%)

EVLO Evelo Biosciences
$11.15 /

-1.34 (-10.73%)

  • 29
    Jan
  • 25
    Jun
RHHBY Roche
$41.64 /

-0.05 (-0.12%)

JNJ Johnson & Johnson
$159.95 /

+0.44 (+0.28%)

RHHBY Roche
$41.64 /

-0.05 (-0.12%)

JNJ Johnson & Johnson
$159.95 /

+0.44 (+0.28%)

JNJ Johnson & Johnson
$159.95 /

+0.44 (+0.28%)

EVLO Evelo Biosciences
$11.15 /

-1.34 (-10.73%)

Hot Stocks
Merck to discontinue development of MRK-7110 in COVID-19 treatment » 06:54
04/15/21
04/15
06:54
04/15/21
06:54
MRK

Merck

$76.40 /

-0.01 (-0.01%)

, JNJ

Johnson & Johnson

$159.95 /

+0.44 (+0.28%)

The company states:…

The company states: "Merck (MRK) announced the discontinuation of development of MK-7110 for the treatment of hospitalized patients with COVID-19. Merck acquired MK-7110 in December 2020 through its acquisition of OncoImmune, a privately-held clinical-stage biopharmaceutical company. As previously reported, Merck subsequently received feedback from the US Food and Drug Administration that additional data, beyond the study conducted by OncoImmune, would be needed to support a potential Emergency Use Authorization application. Based on the additional research that would be required - new clinical trials as well as research related to manufacturing at scale - MK-7110 would not be expected to become available until the first half of 2022. Given this timeline and these technical, clinical and regulatory uncertainties, the availability of a number of medicines for patients hospitalized with COVID-19, and the need to concentrate Merck's resources on accelerating the development and manufacture of the most viable therapeutics and vaccines, Merck has determined to discontinue development of MK-7110 for COVID-19 and to focus its pandemic efforts on advancing molnupiravir and on producing Johnson & Johnson's (JNJ) COVID-19 vaccine."

ShowHide Related Items >><<
MRK Merck
$76.40 /

-0.01 (-0.01%)

JNJ Johnson & Johnson
$159.95 /

+0.44 (+0.28%)

MRK Merck
$76.40 /

-0.01 (-0.01%)

04/12/21 B. Riley
B. Riley calls Agenus the next Seagen, reiterates $8 target
04/08/21 Alliance Global Partners
Alliance Global Partners sees Fast Track for Immutep efti as meaningful positive
04/08/21 H.C. Wainwright
Alkermes collaboration not as big as investors wanted, says H.C. Wainwright
04/07/21 Mizuho
Mizuho sees Alkermes, Merck collaboration as important next step for nemvaleukin
JNJ Johnson & Johnson
$159.95 /

+0.44 (+0.28%)

04/14/21 Guggenheim
Emergent BioSolutions price target lowered to $110 from $130 at Guggenheim
04/13/21 Goldman Sachs
J&J vaccine had numerical blood clot imbalance in trial, says Goldman Sachs
04/13/21 Morgan Stanley
Morgan Stanley says J&J news could improve 2022 outlook for mRNA vaccine makers
04/13/21 JPMorgan
Vaccine pause 'incremental negative' for J&J, says JPMorgan
MRK Merck
$76.40 /

-0.01 (-0.01%)

JNJ Johnson & Johnson
$159.95 /

+0.44 (+0.28%)

MRK Merck
$76.40 /

-0.01 (-0.01%)

JNJ Johnson & Johnson
$159.95 /

+0.44 (+0.28%)

MRK Merck
$76.40 /

-0.01 (-0.01%)

JNJ Johnson & Johnson
$159.95 /

+0.44 (+0.28%)

MRK Merck
$76.40 /

-0.01 (-0.01%)

JNJ Johnson & Johnson
$159.95 /

+0.44 (+0.28%)

Periodicals
Surgeon Gawande tells CNBC J&J vaccine pause should be lifted for older groups » 06:25
04/15/21
04/15
06:25
04/15/21
06:25
JNJ

Johnson & Johnson

$159.95 /

+0.44 (+0.28%)

, AZN

AstraZeneca

$49.87 /

+0.685 (+1.39%)

Dr. Atul Gawande, a…

Dr. Atul Gawande, a surgeon and professor at Harvard's T.H. Chan School of Public Health, told CNBC he believes the pause on Johnson & Johnson's (JNJ) COVID-19 vaccine should continue for younger populations, but should be lifted for older age groups, Emily DeCiccio reports. "I think there is enough information to know that for people over 50 this is safe... I think that that is where this may land, like you saw for AstraZeneca (AZN) in Europe," Gawande told CNBC. Reference Link

ShowHide Related Items >><<
JNJ Johnson & Johnson
$159.95 /

+0.44 (+0.28%)

AZN AstraZeneca
$49.87 /

+0.685 (+1.39%)

JNJ Johnson & Johnson
$159.95 /

+0.44 (+0.28%)

04/14/21 Guggenheim
Emergent BioSolutions price target lowered to $110 from $130 at Guggenheim
04/13/21 Goldman Sachs
J&J vaccine had numerical blood clot imbalance in trial, says Goldman Sachs
04/13/21 Morgan Stanley
Morgan Stanley says J&J news could improve 2022 outlook for mRNA vaccine makers
04/13/21 JPMorgan
Vaccine pause 'incremental negative' for J&J, says JPMorgan
AZN AstraZeneca
$49.87 /

+0.685 (+1.39%)

04/12/21
Fly Intel: Top five analyst downgrades
04/12/21 B. Riley
B. Riley calls Agenus the next Seagen, reiterates $8 target
04/12/21 Argus
AstraZeneca downgraded to Hold from Buy at Argus
JNJ Johnson & Johnson
$159.95 /

+0.44 (+0.28%)

AZN AstraZeneca
$49.87 /

+0.685 (+1.39%)

JNJ Johnson & Johnson
$159.95 /

+0.44 (+0.28%)

AZN AstraZeneca
$49.87 /

+0.685 (+1.39%)

JNJ Johnson & Johnson
$159.95 /

+0.44 (+0.28%)

AZN AstraZeneca
$49.87 /

+0.685 (+1.39%)

JNJ Johnson & Johnson
$159.95 /

+0.44 (+0.28%)

AZN AstraZeneca
$49.87 /

+0.685 (+1.39%)

Periodicals
J&J vaccine pause will likely last another week, FT reports » 06:16
04/15/21
04/15
06:16
04/15/21
06:16
JNJ

Johnson & Johnson

$159.95 /

+0.44 (+0.28%)

The recommendation that…

The recommendation that Johnson & Johnson's COVID-19 vaccine should not be used in the U.S. will likely last another week because members of the Advisory Committee for Immunization practices said there is not yet enough information to change their advice, Kiran Stacey and Nikou Asgari of The Financial Times reports, citing health officials. Reference Link

ShowHide Related Items >><<
JNJ Johnson & Johnson
$159.95 /

+0.44 (+0.28%)

JNJ Johnson & Johnson
$159.95 /

+0.44 (+0.28%)

04/14/21 Guggenheim
Emergent BioSolutions price target lowered to $110 from $130 at Guggenheim
04/13/21 Goldman Sachs
J&J vaccine had numerical blood clot imbalance in trial, says Goldman Sachs
04/13/21 Morgan Stanley
Morgan Stanley says J&J news could improve 2022 outlook for mRNA vaccine makers
04/13/21 JPMorgan
Vaccine pause 'incremental negative' for J&J, says JPMorgan
JNJ Johnson & Johnson
$159.95 /

+0.44 (+0.28%)

JNJ Johnson & Johnson
$159.95 /

+0.44 (+0.28%)

JNJ Johnson & Johnson
$159.95 /

+0.44 (+0.28%)

JNJ Johnson & Johnson
$159.95 /

+0.44 (+0.28%)

Wednesday
Periodicals
Top White House officials to discuss vaccine rollout with House, CNBC says » 17:41
04/14/21
04/14
17:41
04/14/21
17:41
JNJ

Johnson & Johnson

$159.95 /

+0.44 (+0.28%)

, PFE

Pfizer

$37.16 /

+0.01 (+0.03%)

, BNTX

BioNTech

$132.52 /

+3.11 (+2.40%)

, MRNA

Moderna

$160.10 /

+10.62 (+7.10%)

, SPX

S&P 500

/

+

, SPY

SPDR S&P 500 ETF Trust

$411.49 /

-1.34 (-0.32%)

The House coronavirus…

The House coronavirus subcommittee will hear Thursday from three top White House health officials about the U.S.' efforts to increase vaccinations as COVID-19 cases, including those from new variants, are rising, CNBC's Kevin Breuninger reports. The hearing is set to start at 10:30 am ET and will be livestreamed, Breuninger notes. The move comes two days after dozens of states halted the administration of Johnson & Johnson's (JNJ) single dose vaccine in response to the FDA's recommendation that those shots be paused while it looks into cases of women who took the vaccine and developed a rare blood-clotting disorder, the author says. The Fly notes that the U.S. has so far approved COVID-19 vaccines from Pfizer (PFE) and BioNTech (BNTX), and Moderna (MRNA). Reference Link

ShowHide Related Items >><<
SPX S&P 500
/

+

PFE Pfizer
$37.16 /

+0.01 (+0.03%)

MRNA Moderna
$160.10 /

+10.62 (+7.10%)

JNJ Johnson & Johnson
$159.95 /

+0.44 (+0.28%)

BNTX BioNTech
$132.52 /

+3.11 (+2.40%)

JNJ Johnson & Johnson
$159.95 /

+0.44 (+0.28%)

04/14/21 Guggenheim
Emergent BioSolutions price target lowered to $110 from $130 at Guggenheim
04/13/21 Goldman Sachs
J&J vaccine had numerical blood clot imbalance in trial, says Goldman Sachs
04/13/21 Morgan Stanley
Morgan Stanley says J&J news could improve 2022 outlook for mRNA vaccine makers
04/13/21 JPMorgan
Vaccine pause 'incremental negative' for J&J, says JPMorgan
PFE Pfizer
$37.16 /

+0.01 (+0.03%)

04/09/21
Pfizer to host conference call
04/06/21 RBC Capital
Pfizer transferred with a Sector Perform at RBC Capital
BNTX BioNTech
$132.52 /

+3.11 (+2.40%)

02/23/21 B. Riley
B. Riley remains 'aggressive' buyer of Novavax after updated FDA guidance
02/01/21 SVB Leerink
Moderna price target raised to $80 from $69 at SVB Leerink
01/29/21 Piper Sandler
Moderna, Pfizer keep Covid vaccine competitive advantage, says Piper Sandler
01/14/21 Morgan Stanley
80%+ efficacy from J&J vaccine would be 'compelling,' says Morgan Stanley
MRNA Moderna
$160.10 /

+10.62 (+7.10%)

04/13/21 Piper Sandler
Piper reiterates $208 target on Moderna after J&J Covid vaccine pause
04/07/21 Jefferies
Catalent pact with Moderna removes potential overhang, says Jefferies
03/15/21 Piper Sandler
Piper Sandler bullish on Moderna as first subject vaccinated in '1283 study
SPX S&P 500
/

+

03/15/21 Morgan Stanley
Morgan Stanley equity strategist downgrades small cap stocks
03/12/21
On The Fly: Weekly technical notes for S&P 500
01/07/21 Credit Suisse
Credit Suisse raises 2021 S&P 500 target to 4,200, sees 12% upside
11/09/20 JPMorgan
JPMorgan sees S&P 500 hitting 4,000 by early next year
SPY SPDR S&P 500 ETF Trust
$411.49 /

-1.34 (-0.32%)

SPX S&P 500
/

+

PFE Pfizer
$37.16 /

+0.01 (+0.03%)

MRNA Moderna
$160.10 /

+10.62 (+7.10%)

JNJ Johnson & Johnson
$159.95 /

+0.44 (+0.28%)

  • 23
    Jul
  • 19
    May
SPX S&P 500
/

+

PFE Pfizer
$37.16 /

+0.01 (+0.03%)

MRNA Moderna
$160.10 /

+10.62 (+7.10%)

JNJ Johnson & Johnson
$159.95 /

+0.44 (+0.28%)

BNTX BioNTech
$132.52 /

+3.11 (+2.40%)

PFE Pfizer
$37.16 /

+0.01 (+0.03%)

MRNA Moderna
$160.10 /

+10.62 (+7.10%)

JNJ Johnson & Johnson
$159.95 /

+0.44 (+0.28%)

BNTX BioNTech
$132.52 /

+3.11 (+2.40%)

SPY SPDR S&P 500 ETF Trust
$411.49 /

-1.34 (-0.32%)

SPX S&P 500
/

+

PFE Pfizer
$37.16 /

+0.01 (+0.03%)

MRNA Moderna
$160.10 /

+10.62 (+7.10%)

JNJ Johnson & Johnson
$159.95 /

+0.44 (+0.28%)

BNTX BioNTech
$132.52 /

+3.11 (+2.40%)

SPY SPDR S&P 500 ETF Trust
$411.49 /

-1.34 (-0.32%)

SPX S&P 500
/

+

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.